Globus Medical’s Strong Quarterly Earnings Showcase Success in the Medical Device Industry

Globus Medical, a leading medical device company, recently released its quarterly earnings data for the period ending on August 3rd. The results have showcased the company’s strong performance, surpassing analysts’ expectations.

During this quarter, Globus Medical reported earnings per share of $0.63, which exceeded the consensus estimate by $0.03. This positive outcome highlights the company’s ability to generate substantial profits. Additionally, Globus Medical achieved a net margin of 18.63%, indicating its proficiency in managing costs and maximizing profitability.

Moreover, the company demonstrated an impressive return on equity of 12.13%, which indicates its ability to generate returns for shareholders based on the invested capital.

In terms of revenue, Globus Medical achieved $291.62 million for the quarter, surpassing analyst estimates that projected $279.54 million in revenue. This represents a significant increase of 10.6% compared to the same period last year.

Globus Medical specializes in developing and commercializing healthcare solutions for patients suffering from musculoskeletal disorders both domestically and internationally. The company offers a wide range of spine products, including fusion implants, plating systems, intervertebral spacers, and devices for treating various conditions such as degenerative diseases and congenital anomalies.

Furthermore, their portfolio also includes motion preservation technologies designed to provide treatment options for patients seeking alternatives to traditional fusion procedures. These technologies encompass dynamic stabilization, total disc replacement, and interspinous distraction devices.

Additionally, Globus Medical provides interventional pain management solutions aimed at treating vertebral compression fractures—an increasingly common issue among patients—delivering relief and improved quality of life.

Lastly, the company is actively involved in regenerative biologic products with offerings that include allografts (transplants between individuals of the same species) and synthetic alternatives. These products contribute immensely to enhancing patient care by promoting tissue regeneration and supporting natural healing processes.

Overall, Globus Medical’s latest quarterly earnings highlight the company’s strong financial performance and its commitment to advancing healthcare solutions for patients with musculoskeletal disorders. With its impressive earnings per share, net margin, return on equity, and revenue growth, Globus Medical clearly demonstrates its expertise and competitiveness within the medical device industry.

Globus Medical, Inc. Receives Increased Q3 2023 Earnings Estimates and Positive Ratings from Analysts

---

Globus Medical, Inc. (NYSE:GMED) has received an increase in its Q3 2023 earnings estimates, according to a report released by Zacks Research on Wednesday, September 20th. Zacks Research analyst M. Mondal now predicts that the medical device company will post earnings of $0.55 per share for the quarter, up from their previous forecast of $0.54. The consensus estimate for Globus Medical’s current full-year earnings is $2.31 per share, with Zacks Research also issuing estimates for FY2024 earnings at $2.59 EPS.

Several other research analysts have also commented on GMED, including Wells Fargo & Company who decreased their price target on shares of Globus Medical from $63 to $58 and set an “equal weight” rating on the stock in a research note on Friday, September 15th. StockNews.com began coverage on shares of Globus Medical and assigned a “hold” rating to the stock in a research note on Thursday, August 17th.

Barclays also raised their price objective on shares of Globus Medical from $75 to $77 and gave the company an “overweight” rating in a report issued on Monday, August 7th. Truist Financial reaffirmed a “hold” rating and set a $65 price objective on shares of Globus Medical in a report released on Tuesday, September 5th.

TheStreet downgraded shares of Globus Medical from a “b-” rating to a “c+” rating in a report published Thursday, August 31st. Currently, one equities research analyst has given the stock a sell rating while eight have assigned it as hold and four have rated it as buy. According to data from Bloomberg.com, Globus Medical currently has a consensus rating of “Hold” and an average target price of $68.22.

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. Their product offerings include traditional fusion implants, motion preservation technologies, interventional pain management solutions, and regenerative biologic products.

Shares of GMED opened at $51.08 on Friday. The company has a 52-week low of $48.86 and a 52-week high of $80.04. It currently has a market cap of $5.13 billion, a P/E ratio of 25.41, a price-to-earnings-growth ratio of 1.99, and a beta of 1.08. The firm’s 50-day simple moving average is $56.05, while the 200-day simple moving average is $56.38.

In terms of shareholder activity, several hedge funds have recently increased or decreased their stakes in GMED. For instance, Geneos Wealth Management Inc., bought shares valued at $27,000 during the second quarter; Quarry LP purchased shares valued at $27,000 during the first quarter; and EMC Capital Management bought shares valued at $28,000 during the first quarter as well.

Moreover, Advisory Services Network LLC raised its stake in Globus Medical by 109.6% during the first quarter to own 503 shares valued at $28,000 after acquiring an additional 263 shares in the last quarter. Lastly, Altshuler Shaham Ltd acquired new shares valued at $28,000 during the fourth quarter.

It’s important to note that institutional investors and hedge funds currently own approximately 80% of Globus Medical’s stock.

Overall, with Zacks Research increasing earnings estimates for Q3 2023 and positive ratings from various research analysts in the industry along with consistent growth shown by Globus Medical’s innovative medical devices offerings – this remains an interesting stock for potential investors seeking to diversify their portfolios.